8-K: Marker Therapeutics Reports Q3 2024 Financials and Secures NIH Grants for Cancer Therapies

Marker Therapeutics announced its third quarter 2024 financial results, highlighted by progress in its MT-601 clinical trials and the receipt of two NIH grants totaling $4 million.

Summary

• Marker Therapeutics reported its financial results for the third quarter of 2024, ending September 30.
• The company received two grants from the National Institutes of Health (NIH) totaling $4 million to support the development of MT-601 for lymphoma and pancreatic cancer.
• Research and development expenses increased to $3.5 million for the quarter, up from $2.0 million in the same quarter of 2023, due to increased clinical trial activity.
• General and administrative expenses decreased to $0.9 million, compared to $1.4 million in the same quarter of 2023, due to cost savings from a prior reorganization.
• The company reported a net loss of $2.3 million for the quarter, an improvement from the $3.0 million loss in the same quarter of 2023.
• Marker Therapeutics had $9 million in cash and cash equivalents as of September 30, 2024, which they believe will fund operations into October 2025.
• The company is progressing with its Phase 1 APOLLO study for MT-601 in lymphoma, with preliminary safety and efficacy data expected by the end of 2024.
• A clinical program for MT-601 in metastatic pancreatic cancer is expected to begin in 2025.
• The company also anticipates initiating a clinical program for MT-401-OTS in Acute Myeloid Leukemia or Myelodysplastic Syndrome during the first half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the receipt of significant non-dilutive funding, progress in clinical trials, and a reduction in net loss. However, the company is still operating at a loss and has a limited cash runway, which tempers the overall sentiment.

Positives

• The company secured $4 million in non-dilutive funding through NIH grants.
• The company's cash runway extends into October 2025.
• The company reduced general and administrative expenses due to a prior reorganization.
• The net loss decreased compared to the same quarter last year.
• The company is making progress in its clinical trials, with preliminary data expected soon.
• The company is expanding its clinical programs to include pancreatic cancer and AML/MDS.

Negatives

• The company is still operating at a loss.
• Research and development expenses have increased.
• The company has a cash balance of $9 million, which is a decrease from $15.1 million at the end of 2023.

Risks

• The company's ability to fund operations into October 2025 is subject to effective cost management and the utilization of grant funds.
• Clinical trial outcomes are uncertain and may not yield positive results.
• The company is dependent on external funding sources, such as grants, to support its research and development activities.
• The company is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company expects to provide an update on the safety and durability of MT-601 in lymphoma during the fourth quarter of 2024, start a clinical program for MT-601 in metastatic pancreatic cancer in 2025, and initiate a clinical program for MT-401-OTS in AML/MDS during the first half of 2025. The company believes its current cash will fund operations into October 2025.

Management Comments

• Juan Vera, M.D., President and Chief Executive Officer, stated that the company continues to build momentum across its clinical and corporate programs.
• Dr. Vera also mentioned that they are encouraged by the promising activity shown in the MT-601 platform and look forward to continuing assessments from the trial.
• Dr. Vera added that the company continues to make meaningful progress and remains focused on execution as they move their programs through the clinical trials.

Industry Context

This announcement is relevant to the immuno-oncology sector, particularly companies developing T-cell therapies. The company's focus on non-genetically modified T-cell therapies is a differentiating factor in the market. The receipt of NIH grants highlights the potential of their technology and the interest from government funding agencies.

Comparison to Industry Standards

• Marker Therapeutics is developing multiTAA-specific T-cell therapies, which are different from CAR-T cell therapies that are more common in the industry. Companies like Gilead (Kite Pharma) and Novartis are leaders in CAR-T cell therapy, but Marker's approach is focused on non-genetically modified T-cells.
• The company's focus on solid tumors like pancreatic cancer is also notable, as many T-cell therapies have primarily focused on hematological malignancies. Companies like BioNTech and Moderna are also exploring T-cell therapies for solid tumors, but Marker's approach is unique.
• The $4 million in NIH grants is a positive sign, as it provides non-dilutive funding for clinical trials. This is comparable to other biotech companies that receive government funding for research and development.
• The company's cash runway into October 2025 is a key metric, and it will be important to compare this to other companies in the same stage of development. Many biotech companies rely on frequent capital raises to fund their operations.

Stakeholder Impact

• Shareholders may view the NIH grants and clinical trial progress positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be reassured by the company's extended cash runway.

Next Steps

• The company will provide an update on the safety and durability of MT-601 in lymphoma during the fourth quarter of 2024.
• The company will start a clinical program for MT-601 in metastatic pancreatic cancer in 2025.
• The company will initiate a clinical program for MT-401-OTS in AML/MDS during the first half of 2025.

Key Dates

Keywords

Marker Therapeutics, MT-601, MT-401-OTS, Immunotherapy, T cell therapy, Lymphoma, Pancreatic cancer, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Clinical trials, NIH grants, Financial results